RXi and Philips team up for targeted delivery of RNAi therapeutics
This article was originally published in Scrip
Executive Summary
Delivering RNAi therapeutics to their target while keeping them fully active is the goal of a new research agreement between Royal Philips Electronics of the Netherlands and US biopharmaceutical company RXi Pharmaceuticals.